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Abstract
Background: NOD2, an intracellular pathogen recognition sensor, modulates innate defences to
muropeptides derived from various bacterial species, including Mycobacterium tuberculosis (MTB).
Experimentally, NOD2 attenuates two key putative mycobactericidal mechanisms. TNF-α
synthesis is markedly reduced in MTB-antigen stimulated-mononuclear cells expressing mutant
NOD2 proteins. NOD2 agonists also induce resistance to apoptosis, and may thus facilitate the
survival of MTB in infected macrophages. To further define a role for NOD2 in disease
pathogenesis, we analysed NOD2 transcriptional responses in pulmonary leucocytes and
mononuclear cells harvested from patients with pulmonary tuberculosis (PTB).
Methods: We analysed NOD2 mRNA expression by real-time polymerase chain-reaction in
alveolar lavage cells obtained from 15 patients with pulmonary tuberculosis and their matched
controls. We compared NOD2 transcriptional responses, in peripheral leucocytes, before and
after anti-tuberculous treatment in 10 patients. In vitro, we measured NOD2 mRNA levels in MTB-
antigen stimulated-mononuclear cells.
Results: No significant differences in NOD2 transcriptional responses were detected in patients
and controls. In some patients, however, NOD2 expression was markedly increased and
correlated with toll-like-receptor 2 and 4 expression. In whole blood, NOD2 mRNA levels
increased significantly after completion of anti-tuberculosis treatment. NOD2 expression levels did
not change significantly in mononuclear cells stimulated with mycobacterial antigens in vitro.
Conclusion: There are no characteristic NOD2 transcriptional responses in PTB. Nonetheless,
the increased levels of NOD2 expression in some patients with severe tuberculosis, and the
increases in expression levels within peripheral leucocytes following treatment merit further
studies in selected patient and control populations.
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The innate immune system is postulated to play a crucial
role in the elimination or control of Mycobacterium tuber-
culosis (MTB), which causes infectious tuberculosis [1,2].
These innate immune responses are triggered when MTB-
derived molecules are sensed by toll-like receptors (TLRs),
a family of membrane proteins, as well as by nucleotide-
binding oligomerization domain 2 (NOD2; also known
as CARD15), an intracellular pathogen recognition sen-
sor. Activation of TLRs by MTB-antigens appears to be an
important event in the control of infection. For example,
mice that lack the toll-like receptor (TLR) adaptor mole-
cule myeloid differentiation factor 88 (MyD88) are more
susceptible to pneumonia following aerogenic infection
with MTB [3].
The nature of these innate responses, however, appears
complex and is not fully elucidated. For example, experi-
mental studies show that MTB-induced TLR signalling
effects both cellular activation [4] and apoptosis [5]. Sim-
ilarly, the innate responses mediated by NOD2, in
response to MTB-derived antigens, vary in different exper-
imental systems.
NOD2 senses muramyl dipeptide (MDP) [6,7] a compo-
nent of peptigoglycan that is found in mycobacterial cell
walls. A recent in vitro study suggests that NOD2 is an
essential recognition molecule for MTB [8], and pro-
nounced cellular activation is noted in NOD2-transfected
cells that are stimulated with MDP or heat-killed MTB
preparations. Furthermore, cytokine production is inhib-
ited in MTB-stimulated peritoneal macrophages obtained
from NOD2-deficient mice and in human peripheral
blood mononuclear cells (PBMCs) that express truncated
NOD2 proteins [8]. On the other hand, MDP stimulation
protects macrophages from apoptosis, which suggests that
activation of NOD2 induces apoptosis resistance which
facilitates the survival of MTB in macrophages [5].
The role of NOD2 in the pathogenesis of human MTB-
infection is unknown. In vitro, human PBMCs that express
truncated NOD2 proteins synthesise significantly less
cytokines after stimulation with MTB-derived antigens.
Truncated NOD2 proteins are encoded by mutations in
the NOD2 gene that predispose individuals to Crohn's
disease, a granulomatous inflammatory bowel disease
[9,10]. The prevalence of these Crohn's disease-associated
mutations has not been fully described in all population
groups where tuberculosis is endemic although these
mutations are rare in African patients with tuberculosis
[11].
To further define a role for NOD2 in disease pathogenesis,
we analysed NOD2 mRNA transcriptional responses in
pulmonary leucocytes and PBMCs harvested from
patients with pulmonary tuberculosis (PTB) and healthy
controls. We determined whether changes in NOD2 tran-
scription, if present, are characteristic for patients with
tuberculosis: increased transcriptional responses may sug-
gest that MTB-infected macrophages are resistant to apop-
tosis whereas decreased transcriptional responses may
suggest that cellular activation is diminished in infected
macrophages. As various pathogen associated-molecular
patterns (PAMPs) specifically alter host transcriptional
responses [12], we analysed and correlated the transcrip-
tional responses of other TLRs with NOD2 in patients
with PTB.
Methods
Patients and samples
Fifteen HIV-negative patients with culture proven pulmo-
nary tuberculosis (PTB), who donated blood and lung
bronchoalveolar lavage (BAL) samples, were recruited in
London, United Kingdom. All patients with PTB had pan-
sensitive isolates, received standard short course chemo-
therapy (6 to 9 months) and demonstrated clinical and
radiological response to anti-TB treatment. Control
donors (n = 15) were healthy volunteers matched to the
TB patients for age (within 4 years), sex and ethnicity.
They were asymptomatic, had no risk factors for HIV
infection (but were not formally tested), had normal chest
radiographs and were assumed, based on antigen-specific
(ESAT-6 and CFP-10) peripheral mononuclear cell IFN-γ
responses, not to be latently infected (T SPOT TB, Oxford
Immunotec, England) [13]. Control BAL samples were
obtained from six control donors.
Whole blood (20 mL) was taken, after informed consent,
within the first 2 weeks of anti-TB treatment (baseline).
2.5 mL whole blood was immediately transferred into
PAXgene Blood RNA Tubes (Qiagen) for isolation and
purification of intracellular RNA. The remaining blood,
where relevant, was used for further experiments. Ten
donors with PTB were bled again within 4 weeks of stop-
ping chemotherapy. Approval was obtained from the
Royal Free and UCLH hospital ethics committees.
BAL and Radiographic scoring
BAL fluid, obtained from a radiologically affected lung
segment, was concentrated ~10 fold before analysis whilst
cell pellets were immediately fixed in RNA stabilisation
buffer. In control donors the right middle lobe was lav-
aged. When possible, lymphocyte counts in BAL were con-
firmed by flow cytometry (104 gated events) after staining
~7.5 × 105 cells with anti CD4-FITC, anti CD8-PE and anti
CD3-PercP antibodies (BD Biosciences, UK). To deter-
mine the extent of pre-treatment radiological disease, two
radiologists, blinded to patient details, scored chest radio-
graphs for air space shadowing, reticular opacities and
cavitation.Page 2 of 9
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Peripheral T-cell IFN-γ ELISPOT responses to ESAT-6 and
CFP-10 peptide pools were determined to exclude latent
TB infection (T SPOT TB, Oxford Immunotec, England),
as previously described [14,13,15].
Culture and infection of PBMCs with M. tuberculosis
PBMCs from five healthy control donors were separated
from heparinized blood (50 ml) by Ficoll density gradient
centrifugation, and cells were reconstituted at a final con-
centration of 1 × 106 cells/ml. To evaluate NOD2 gene reg-
ulation PBMCs were cultured for 66 hours in the presence
of live H37RV M. tuberculosis, a clinical isolate (Beijing
strain), live environmental mycobacterium (M. vaccae
NCTC 11659) and medium alone. Cells were cultured in
RPMI 1640 supplemented with 5% heat-inactivated
human AB serum and 1% L-glutamine without antibiotics
at 37°C and 5% CO2 in a category 3 laboratory and har-
vested at 18, 24, 48, and 66 h post-treatment. All strains
were grown in Middlebrook 7H10 agar (Difco) contain-
ing 10% v/v oleic acid/albumin/dextrose/catalase supple-
ment (BD Biosciences) in the category 3 laboratory.
Mycobacteria were disaggregated by vigorous vortexing
with glass beads and counted using a Neubauer hemocy-
tometer as previously described [16]. A direct microscopic
count was performed to determine mycobacterial concen-
tration. PBMCs were infected with living mycobacteria at
a dose of 1 organism per macrophage (10% monocytes in
PBMC). The viability of mycobacteria was assessed by cul-
turing the diluted bacteria on Middlebrook 7H10 agar.
Reverse transcription and real-time PCR
RNA was isolated from whole blood and from lavage cell
pellets or cells using the Paxgene® and RNeasy® Kit, respec-
tively. Reverse transcription and real-time PCR, to quan-
tify mRNA encoding for NOD2 and NOD1, IL-4 and its
splice variant IL-4δ2, IFN-γ, TLRs and several proteins
involved in apoptosis (FLIP, FLICE, Bcl-2, Bax, Fas, FasL
and Bfl-1), were performed on samples, as previously
described, after quality control of RNA templates [17].
mRNA values were normalised to a validated housekeep-
ing gene, human-acidic-ribosomal-protein (HuPO)
[18,19]. Primer and probe sequences, excluding those
which have been previously published [16,17], are shown
in table 2.
Data analysis
Data was analysed using the Mann-Whitney U test, Wil-
coxon matched pairs test, Spearman rank-sum correlation
and linear regression on logged data.
Results
Demographic characteristics
Demographic details of matched TB patients (n = 15) and
controls, shown in Table 1, indicate that there were no dif-
ferences in baseline characteristics between these groups.
All control patients had normal chest radiographs and
had no laboratory evidence of latent TB infection with M.
tuberculosis, as assessed by the antigen specific IFN-γ assay
(T SPOT TB).
Table 1: Demographic details and lavage cell counts at recruitment. Demographic details and radiographic scores are of 15 patients 
with pulmonary tuberculosis with their matched controls; the lavage cell counts are those of 10 patients and 6 controls. All 
participants were recruited in London, United Kingdom.
Numbers in parenthesis indicate % TB Control
Age (median; range in years) 28; 18–52 28; 19–48
Sex (male) 9 (60) 8 (53)
Ethnicity
Black African 9 (60) 8 (53)
Indian 4 (26) 4 (26)
Other 2 (14) 3 (21)
X-ray features
Cavitation 8 (53) 0
>50% airspace shadowing of total lung field 7 (47) 0
BAL (mean ± SE)
Total leucocytes (× 104/ml) 31 ± 8 12.8 ± 4.2
lymphocyte count (× 104/ml) 15 ± 4 2.7 ± 1.4
CD4: CD8 ratio 3.8 ± 1 2.55 ± 0.9
IFN-γ copy number 3390 [1525–7498] 13 [4–113]; p = 0.0005
Th1/Th2 ratio 3.5 [3.1–3.8] 1.1 [.4–1.8]; p = 0.0007Page 3 of 9
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with PTB and controls
BAL fluid recovered from patients with PTB were more cel-
lular than controls, contained predominantly alveolar
macrophages, and contained a significantly greater
number of leucocytes and lymphocytes (Table 1). In PTB-
affected patients, IFN-γ mRNA levels and the Th1/Th2
(IFN-γ/IL-4) ratio were significantly elevated compared to
control subjects (Table 1).
Pulmonary leucocytes express NOD2 mRNA
NOD2 is most prominently expressed in circulating
monocytes [10] and small intestinal Paneth cells [20].
Expression profiles in human pulmonary leucocytes have
not previously been studied. We initially determined
whether alveolar macrophages express NOD2 and meas-
ured NOD2 mRNA levels in pulmonary leucocytes
present in BAL fluid [21]. We show that NOD2 mRNA
expression levels are prominent in pulmonary leucocytes
although expression levels did not differ between patients
and controls (Figure 1). We also compared the expression
levels of NOD1 mRNA (also known as CARD4), in pul-
monary leucocytes obtained from patients and controls
(Figure 1). NOD1 is an intracellular protein that is closely
related to NOD2 but does not appear to play a role in the
detection of mycobacterial antigens [8].
Although there are no characteristic NOD2 transcriptional
responses in patients with PTB, NOD2 mRNA was highly
expressed in two patients. Both patients, who were of
Somalian origin, and had severe tuberculosis: one patient
had extensive pulmonary cavitatory disease and the other
disseminated tuberculosis. We could not, however, iden-
tify more specific clinical variables to account for the high
levels of NOD2 expression in these patients. Patients with
cavitatory disease tended to have higher levels of NOD2
mRNA expression than those without pulmonary cavita-
tion but these differences were not significant (Figure 2).
There was no correlation between NOD2 mRNA levels
and radiographic disease scores.
NOD2, and TLR2 and TLR4 mRNA expression correlate in 
pulmonary leucocytes obtained from patients with PTB
NOD2 regulates cellular responses to peptidoglycan-
mediated activation of TLR2 [22]. Furthermore, mycobac-
terial TLR2 and NOD2 agonists synergistically induce
cytokine release in PBMCs obtained from healthy volun-
teers and patients with Crohn's disease [8]. In pulmonary
leucocytes obtained from patients with tuberculosis,
NOD2 mRNA expression correlated with TLR2 (p = 0.02;
figure 3A) and TLR4 (p = 0.01; figure 3B) but not with
TLR6 mRNA expression (p = 0.17). These correlations
were mainly due to the high levels of mRNA expression in
the two previously mentioned patients. In healthy con-
trols, there was no correlation between NOD2 and TLR2
Table 2: Primer and probe sequences used to quantify gene 
expression by real-time PCR. Primer sequences for toll-like-
receptor 2, 4, 6, 7 and 9 [17] and IL-4δ2 [18] have previously 
been published.
Genes * Probe sequence 5'-(FAM-TAMRA)-3'
? L primer-5'-3'
 R primer-5'-3'
Product size
IL-4 * AAACCTTCTGCAGGGCTGCGAC 71 bp
? GCTGCCTCCAAGAACACAAC
 CTGTAGAACTGCCGGAGCAC
HuPO *TGCCAGTGTCTGTCTGCAGATTG
G
105 bp
? GCTTCCTGGAGGGTGTCC
 GGACTCGTTTGTACCCGTTG
NOD1 * CCTGGCTCCGACATCGGTGA 133 bp
? AAGCGAAGAGCTGACCAAAT
 TCCCAGTTTAAGATGCGTGA
NOD2 * CCGAGGCATCTGCAAGCTCA 82 bp
? CTGCAAGGCTCTGTATTTGC
 CTCGCAGTGAAGAGCACATT
TNF-α * CAGCCACTGGAGCTGCCCCT 102 bp
? AGCCCATGTTGTAGCAAACC
 GCTGGTTATCTCTCAGCTCCA
FLIP * 
TGGATTGCTGCTTGGAGAACATT
CC
114 bp
? GTTCAAGGAGCAGGGACAAG
 ATCAGGACAATGGGCATAGG
FLICE * 
ACTTGGATGCAGGGGCTTTGACC
AC
102 bp
? AAGTGCCCAAACTTCACAGC
 GGGGCTTGATCTCAAAATGA
Bax * 
AAGTAGAAAAGGGCGACAACCCG
GC
105 bp
? GAGAGGTCTTTTTCCGAGTGG
 GCCTTGAGCACCAGTTTGCTG
Bfl-1 * 
CCACAACCTGGATCAGGTCCAAG
CA
105 bp
? GGCTGGCTCAGGACTATCTG
 TTTGGACTGAGAACGCAACA
Bcl-2 * 
CAAAGGCATCCCAGCCTCCGTTA
118 bp
? AGTACCTGAACCGGCACCT
 TTCAGAGACAGCCAGGAGAAAPage 4 of 9
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NOD1 mRNA expression did not correlate with TLR2 or
TLR4 mRNA expression in pulmonary leucocytes
obtained from patients and controls.
NOD2 expression increases in whole blood following anti-
tuberculous therapy
In whole blood, both NOD2 and NOD1 mRNA expres-
sion increased following treatment, although only
increases in NOD2 mRNA expression were significant
(Figure 4).
Signalling pathways activated by NOD2
Following activation by MDP, NOD2 triggers down-
stream cellular responses mediated through NF-κB and
mitogen-activated protein kinase (MAPK) activation [23].
This results in the production of various cytokines, such as
TNFα and IL-4, which are important in regulating
immune responses to MTB [1,17]. We therefore compared
NOD2 mRNA with the transcriptional responses of
selected cytokines in BAL-derived cells obtained from
patients with PTB (n = 15) and controls (n = 6). Although
there were clear differences in the expression of some
cytokines (IFNγ, IL-4 and its splice variant and antagonist,
IL-4δ2) in patients with TB and controls, there was no cor-
relation between expression of these cytokines and
NOD2. There was also no correlation between NOD2 and
TNFα transcriptional responses in patients and controls.
In addition, NOD2 mRNA expression did not correlate
with expression of mRNA encoding several proteins
involved in apoptosis (FLIP, FLICE, Bcl-2, Bax, Fas, FasL
and Bfl-1) although high levels of mRNA encoding the
anti-apoptotic protein FLICE were measured in BAL-
derived cells obtained from the two patients with elevated
NOD2 mRNA levels.
NOD2 mRNA expression is not regulated in PMBC freshly 
inoculated with live strains of mycobacteria
We exposed PBMCs from five healthy volunteers, who did
not have laboratory evidence of tuberculosis infection (as
established by antigen-specific IFN-γ assays [14,13,15]),
to pathogenic strains of live mycobacteria (H37RV and
Beijing strain) and an environmental mycobacterium (M.
vaccae NCTC 11659), to determine if NOD2 mRNA
expression levels are regulated by. In general, mycobacte-
ria induced modest, but non-significant changes, in
NOD2 mRNA expression (Figure 5A). Mycobacteria
induced marked increases in NOD2 mRNA expression in
one volunteer (Figure 5B) although mycobacterial stimu-
lation did not regulate NOD2 mRNA expression signifi-
cantly in PBMC extracted from the other volunteers
NOD2 gene expression in alveolar lavage cells from 15 sub-jects with tuberculo s (stratified by whether cavitation was detected on chest radiographs) and 6 althy controlsFigur  2
NOD2 gene expression in alveolar lavage cells from 15 sub-
jects with tuberculosis (stratified by whether cavitation was 
detected on chest radiographs) and 6 healthy controls.
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BMC Infectious Diseases 2007, 7:96 http://www.biomedcentral.com/1471-2334/7/96(Figure 5C–F). In these studies, NOD2 mRNA expression
levels varied widely and did not correlate with any specific
mycobacterial strain.
Discussion
NOD2, a member of the phylogenetically conserved NLR
(NACHT-leucine-rich repeat) family, is an essential pat-
tern recognition sensor for MTB-derived antigens. Myco-
bacterial antigens fail to induce an appropriate increase in
TNF-α synthesis in human PBMC that express mutant
NOD2 proteins and in murine macrophages lacking
NOD2 [8]. The gene mutations that encode mutant
NOD2 proteins, however, appear to be rare in patients
with tuberculosis. NOD2 agonists may also modulate
innate responses to MTB by inducing resistance to apop-
tosis that facilitates the survival of MTB in infected macro-
phages [5]. Thus, NOD2 may play a role in attenuating
two key putative mycobactericidal pathways. To further
define a role for NOD2 in disease pathogenesis, we ana-
lysed NOD2 transcriptional responses in pulmonary leu-
cocytes and mononuclear cells harvested from patients
with pulmonary tuberculosis (PTB).
Our gene expression studies revealed that there are no
characteristic NOD2 transcriptional responses in pulmo-
nary leucocytes obtained from patients with tuberculosis.
NOD2 mRNA levels in patients generally compared with
those in control donors. Nonetheless, increased NOD2
levels, which correlate with TLR2 and TLR4 expression,
were noted in some patients with severe infection. This
observation, coupled with the increases in NOD2 expres-
NOD1 and NOD2 mRNA expression in peripheral blood cells obtained from patients with tuberculosis, b fore an  after an i-tuberculous reatmentFigure 4
NOD1 and NOD2 mRNA expression in peripheral 
blood cells obtained from patients with tuberculosis, 
before and after anti-tuberculous treatment. NOD1 
and NOD2 mRNA expression was analysed, by real-time 
RT-PCR, in peripheral blood cells isolated from patients with 
tuberculosis and matched controls. To permit comparison 
between individuals, absolute copy numbers of NOD2 (4A) 
and NOD1 (4B) mRNA were measured during RT-PCR, 
using cDNA standards, and expressed relative to 106 mRNA 
copies of a validated housekeeping gene HuPO. NOD2 but 
not NOD1 mRNA levels increased significantly after treat-
ment.
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BMC Infectious Diseases 2007, 7:96 http://www.biomedcentral.com/1471-2334/7/96sion in peripheral leucocytes following treatment, suggest
further study in a larger group of patients to confirm a role
for NOD2 in PTB. In the present study, we only measured
total leucocyte and lymphocyte counts in bronchoalveo-
lar lavage fluid. As NOD2 is most prominently expressed
in monocytes, with very little expression in neutrophils
and lymphocytes, it is most likely that monocytes account
for the overwhelming majority of NOD2 expression [24].
We did not quantify the number of epithelial cells present
in broncho-alveolar fluid and we cannot determine the
effect of mycobacterial infection on NOD2 expression in
respiratory epithelial cells. Baseline NOD2 expression lev-
els in primary respiratory epithelial cells is low [25]
although NOD2 mRNA expression is enhanced in immor-
talised human bronchial epithelial cells that are infected
with Streptococcus pneumoniae[25]. It would therefore be
important to determine the relative contribution of respi-
ratory epithelial cells and monocytes to the increases in
NOD2 expression seen in some patients.
In the present study, NOD2 mRNA expression levels were
similar in patients (who often have active disease for
many weeks prior to diagnosis) and controls. This does
not exclude a role for NOD2 during the early stages of
MTB infection, when M. tuberculosis encounters the alveo-
lar macrophage and innate immune pathways are first
activated. It is also possible, however, that the absolute
levels of NOD2 expression may not play a role in deter-
mining susceptibility to MTB infection. Rather, structural
variants of NOD2 proteins may modulate host immune
responses as suggested by in vitro studies [8]. Thus, studies
NOD2 mRNA expression in live mycobacteria stimulated-peripheral blood cells obtained from healthy volunteersFigure 5
NOD2 mRNA expression in live mycobacteria stimulated-peripheral blood cells obtained from healthy volun-
teers. NOD2 mRNA levels varied widely in healthy donor derived-PBMCs that were stimulated with live mycobacterial strains 
[A = combined data and B to F individual data]. NOD2 mRNA expression was analysed, by real-time RT-PCR, in peripheral 
blood cells isolated from healthy donors. To permit comparison between individuals, absolute copy numbers of NOD2 mRNA 
were measured during RT-PCR, using cDNA standards, and expressed relative to 106 mRNA copies of a validated housekeep-
ing gene HuPO. Lower numbers of PBMCs were harvested from Donors 1 and 3, and these cells were not stimulated with 
Mycobacterium vaccae. MV = M, vaccae; H37 = H37RV strain and CPA = Beijing strain.
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BMC Infectious Diseases 2007, 7:96 http://www.biomedcentral.com/1471-2334/7/96are required to confirm whether individuals with gene
mutations encoding for mutant NOD2 proteins are pre-
disposed to MTB-infection. The lack of an association
between Crohn's disease-associated NOD2 gene muta-
tions and tuberculosis in African patients [11] does not
exclude a role for NOD2 in MTB-infection because NOD2
gene mutations are probably rare in African populations
[10]. It would be instructive, therefore, to determine
whether NOD2 gene mutations are associated with MTB-
infection in Caucasian populations, where these muta-
tions occur with much greater frequency.
We were surprised to find significantly higher levels of
NOD2 mRNA expression in peripheral leucocytes
obtained from patients who completed anti-tuberculosis
therapy. Firstly, we hypothesise that this could have been
due to translocation of antigen-specific leucocytes pre-
dominantly to the site of disease (lungs) with few NOD2
expressing leucocytes in the peripheral compartment, and
reversal of this profile after treatment. However, the lack
of preferential NOD2 upregulation in the lung makes this
unlikely. Secondly, we speculate that MTB infection may
subvert protective innate responses by downregulating
NOD2 expression, whose levels therefore increase after
successful chemotherapy. We might expect this to occur in
parallel with TNF-α as this cytokine up-regulates NOD2
mRNA expression in various cell lineages including PBMC
[26,27]. However, in keeping with the observations of
other investigators [28,29], we did not observe increased
TNF-α mRNA expression after treatment completion. We
did not investigate the relationship between NOD2 and
soluble TNF-α receptors, which may modulate TNF-α lev-
els. Thirdly, it is intriguing to speculate that increased lev-
els of NOD2 mRNA, which occur with completion of TB
treatment, is a correlate of protective immunity. Similar
longitudinal changes may occur with IFN-γ [17,29,30]
and the Th1-like splice variant IL-4δ2 [17], which both
increase significantly with anti-TB treatment. In keeping
with these observations IL-4δ2 mRNA levels are also
increased in healthy subjects with latent MTB infection
who contain the disease [31,32]. Longitudinal studies in
TB infected patients, however, would be required to
address the role of NOD2 in this context. Interestingly,
preliminary data indicate that mycobacterial antigens reg-
ulate the expression of NOD2 splice variants [33] and fur-
ther studies are required to clarify their role in
tuberculosis.
A significant limitation of this study is that we did not
study MTB-specific responses in subjects with known
NOD2 gene mutations. However, we found these patients
difficult to recruit in our clinical setting. We also acknowl-
edge that real time PCR measures steady state mRNA lev-
els only and not the activity of NOD2 protein, which is
physiologically active at concentrations too low to detect
by immunoassay. This study was powered to detect a 0.5
log change in NOD2 mRNA levels although smaller
changes may be biologically meaningful. However,
mRNA levels in patients and controls were similar and we
found no trends suggesting that inter-group difference
might be present.
Conclusion
Overall, our findings show that there are no characteristic
NOD2 transcriptional responses in pulmonary leucocytes
obtained from patients with PTB. Nonetheless, the
increased levels of NOD2 mRNA expression in peripheral
leucocytes obtained from patients completing treatment
and correlation between NOD2 and TLR2 and TLR4
mRNA expression in pulmonary leucocytes obtained from
some patients with severe tuberculosis does not exclude a
role for NOD2 in disease pathogenesis. The role of mutant
NOD2 proteins in MTB-infection in different ethnic
groups needs to be defined.
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